Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model

Hippocampal metabotropic glutamate receptor long-term depression in health and disease: focus on mitogen-activated protein kinase pathways

(2016) Thomas M. Sanderson et al.   JOURNAL OF NEUROCHEMISTRY

Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS

(2015) Sally M. Till et al.   HUMAN MOLECULAR GENETICS

Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release

(2015) S.-H. Lee et al.   JOURNAL OF NEUROSCIENCE

Minireview: From the Bench, Toward the Clinic: Therapeutic Opportunities for Cannabinoid Receptor Modulation

(2015) Robert P. Picone et al.   MOLECULAR ENDOCRINOLOGY

Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner

(2015) Ferenc Zádor et al.   NEUROPHARMACOLOGY

Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome

(2015) Lara Costa et al.   Frontiers in Behavioral Neuroscience

New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model

(2014) Arnau Busquets-Garcia et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Genetic Removal of Matrix Metalloproteinase 9 Rescues the Symptoms of Fragile X Syndrome in a Mouse Model

(2014) H. Sidhu et al.   JOURNAL OF NEUROSCIENCE

Targeting the endocannabinoid system in the treatment of fragile X syndrome

(2013) Arnau Busquets-Garcia et al.   NATURE MEDICINE

Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome

(2013) Emily K. Osterweil et al.   NEURON

Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders

(2012) Cristoforo Silvestri et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity

(2012) F J Meye et al.   MOLECULAR PSYCHIATRY

Genetic Removal of p70 S6 Kinase 1 Corrects Molecular, Synaptic, and Behavioral Phenotypes in Fragile X Syndrome Mice

(2012) Aditi Bhattacharya et al.   NEURON

Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice

(2012) Aubin Michalon et al.   NEURON

Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen

(2012) C. Henderson et al.   Science Translational Medicine

Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome

(2012) Kwang-Mook Jung et al.   Nature Communications

Defective GABAergic Neurotransmission and Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a Mouse Model of Fragile X Syndrome

(2010) J. L. Olmos-Serrano et al.   JOURNAL OF NEUROSCIENCE

Enhanced Endocannabinoid Signaling Elevates Neuronal Excitability in Fragile X Syndrome

(2010) L. Zhang et al.   JOURNAL OF NEUROSCIENCE

Mechanism-based approaches to treating fragile X

(2010) Gül Dölen et al.   PHARMACOLOGY & THERAPEUTICS

Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome

(2010) A. Suvrathan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fragile X syndrome: from molecular genetics to therapy

(2009) C D'Hulst et al.   JOURNAL OF MEDICAL GENETICS

Central and peripheral consequences of the chronic blockade of CB1cannabinoid receptor with rimonabant or taranabant

(2009) Elena Martín-García et al.   JOURNAL OF NEUROCHEMISTRY

Endocannabinoid-Mediated Control of Synaptic Transmission

(2009) Masanobu Kano et al.   PHYSIOLOGICAL REVIEWS

Abnormal Striatal GABA Transmission in the Mouse Model for the Fragile X Syndrome

(2007) Diego Centonze et al.   BIOLOGICAL PSYCHIATRY

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL